Literature DB >> 22884125

Pathogenic role of anti-M3 muscarinic acetylcholine receptor immune response in Sjögren's syndrome.

Takayuki Sumida1, Mana Iizuka, Hiromitsu Asashima, Hiroto Tsuboi, Isao Matsumoto.   

Abstract

M3 muscarinic acetylcholine receptor (M3R) is expressed in exocrine glands (e.g., salivary glands [SGs] and lachrymal glands), and plays a crucial role in exocrine secretion. M3R reactive T cells have been detected in circulating mononuclear cells of 40% of patients with Sjögren's syndrome (SS), and the major T cell epitopes of M3R in those patients with HLA-DR B1×0901 are located in the second loop of M3R. Moreover, autoantibodies (autoAbs) against M3R are also present in sera of around 50% of patients with SS, and several B cell epitopes, such as N-region, 1st, 2nd, and 3rd loop of M3R, have been identified. Functional analysis using human SG cell lines showed that autoAbs against the 2nd loop of M3R suppressed intracellular Ca(2+) influx, suggesting inhibition of saliva secretion. To clarify whether the M3R reactive immune response induces autoimmune sialadenitis (AIS), M3R(-/-) mice were immunized with M3R synthetic peptides and their splenocytes transferred into Rag1(-/-) mice. The recipients developed severe sialadenitis, and cell transfer studies indicated that T cells are key factors in the pathogenesis of AIS. These results indicate that the M3R immune reaction plays a key pathogenic role in AIS, suggesting that M3R molecule acts as an autoantigen in the pathogenesis of SS.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22884125     DOI: 10.1016/j.lpm.2012.05.019

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  7 in total

Review 1.  Childhood Sjögren syndrome: insights from adults and animal models.

Authors:  Scott M Lieberman
Journal:  Curr Opin Rheumatol       Date:  2013-09       Impact factor: 5.006

2.  Possible Mechanisms of Lymphoma Development in Sjögren's Syndrome.

Authors:  Lingli Dong; Yu Chen; Yasufumi Masaki; Toshiro Okazaki; Hisanori Umehara
Journal:  Curr Immunol Rev       Date:  2013-02

Review 3.  Sjögren's syndrome: still not fully understood disease.

Authors:  Maria Maślińska; Małgorzata Przygodzka; Brygida Kwiatkowska; Katarzyna Sikorska-Siudek
Journal:  Rheumatol Int       Date:  2014-07-02       Impact factor: 2.631

Review 4.  Innate Immunity and Biological Therapies for the Treatment of Sjögren's Syndrome.

Authors:  Amrita Srivastava; Helen P Makarenkova
Journal:  Int J Mol Sci       Date:  2020-12-01       Impact factor: 5.923

Review 5.  Salivary Biomarkers in Patients with Sjögren's Syndrome-A Systematic Review.

Authors:  Ju-Yang Jung; Ji-Won Kim; Hyoun-Ah Kim; Chang-Hee Suh
Journal:  Int J Mol Sci       Date:  2021-11-29       Impact factor: 5.923

6.  Clinical usefulness of anti-muscarinic type 3 receptor autoantibodies in patients with primary Sjögren's syndrome.

Authors:  Mahmoud Mona; Stefania Mondello; Joon Young Hyon; Wafaa Saleh; Kyudong Han; Hyo-Jung Lee; You-Jung Ha; Eun Ha Kang; Yun Jong Lee; Seunghee Cha
Journal:  Clin Exp Rheumatol       Date:  2020-10-06       Impact factor: 4.473

Review 7.  Interactions between developing nerves and salivary glands.

Authors:  João N Ferreira; Matthew P Hoffman
Journal:  Organogenesis       Date:  2013-06-06       Impact factor: 2.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.